The study investigates the effectiveness of preoperative neoadjuvant chemoradiotherapy (NACRT) in patients with borderline resectable (cT3br) thoracic esophageal cancer compared to those with resectable (cT3r) cases.
Out of 186 patients, 68 were cT3br and showed significantly more advanced disease characteristics but had similar overall survival rates post-surgery compared to the cT3r group.
The results suggest that NACRT could be a beneficial treatment option for patients with borderline resectable thoracic esophageal squamous cell carcinoma.